Randomized clinical trial of an ethanol extract of Ganoderma lucidum in men with lower urinary tract symptoms

Masanori Noguchi, Tatsuyuki Kakuma, Katsuro Tomiyasu, Akira Yamada, Kyogo Itoh, Fumiko Konishi, Shoichiro Kumamoto, Kuniyoshi Shimizu, Ryuichiro Kondo, Kei Matsuoka

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Aim: To evaluate the safety and efficacy of an extract of Ganoderma lucidum that shows the strongest 5α-reductase inhibitory activity among the extracts of 19 edible and medicinal mushrooms by a double-blind, placebo-controlled, randomized and dose-ranging study in men with lower urinary tract symptoms (LUTS). Methods: In this trial, we randomly assigned 88 men over the age of 49 years who had slight-to-moderate LUTS to 12 weeks of treatment with G. lucidum extract (6 mg once a day) or placebo. The primary outcome measures were changes in the International Prostate Symptom Score (IPSS) and variables of uroflowmetry. Secondary outcome measures included changes in prostate size, residual urinary volume after voiding, laboratory values and the reported adverse effects. Results: G. lucidum was effective and significantly superior to placebo for improving total IPSS with 2.1 points decreasing at the end of treatment (mean difference, -1.18 points; 95% confidence interval, -1.74 to -0.62; P < 0.0001). No changes were observed with respect to quality of life scores, peak urinary flow, mean urinary flow, residual urine, prostate volume, serum prostate-specific antigen or testosterone levels. Overall treatment was well tolerated with no severe adverse effects. Conclusion: The extract of G. lucidum was well tolerated and improved IPSS scores. These results encouraged a further, large-scale evaluation of phytotherapy for a long duration using the extract of G. lucidum on men with LUTS.

Original languageEnglish
Pages (from-to)777-785
Number of pages9
JournalAsian Journal of Andrology
Volume10
Issue number5
DOIs
Publication statusPublished - Aug 29 2008

Fingerprint

Reishi
Lower Urinary Tract Symptoms
Prostate
Ethanol
Randomized Controlled Trials
Placebos
Outcome Assessment (Health Care)
Phytotherapy
Residual Volume
Agaricales
Prostate-Specific Antigen
Testosterone
Oxidoreductases
Therapeutics
Quality of Life
Urine
Confidence Intervals
Safety
Serum

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Randomized clinical trial of an ethanol extract of Ganoderma lucidum in men with lower urinary tract symptoms. / Noguchi, Masanori; Kakuma, Tatsuyuki; Tomiyasu, Katsuro; Yamada, Akira; Itoh, Kyogo; Konishi, Fumiko; Kumamoto, Shoichiro; Shimizu, Kuniyoshi; Kondo, Ryuichiro; Matsuoka, Kei.

In: Asian Journal of Andrology, Vol. 10, No. 5, 29.08.2008, p. 777-785.

Research output: Contribution to journalArticle

Noguchi, M, Kakuma, T, Tomiyasu, K, Yamada, A, Itoh, K, Konishi, F, Kumamoto, S, Shimizu, K, Kondo, R & Matsuoka, K 2008, 'Randomized clinical trial of an ethanol extract of Ganoderma lucidum in men with lower urinary tract symptoms', Asian Journal of Andrology, vol. 10, no. 5, pp. 777-785. https://doi.org/10.1111/j.1745-7262.2008.00361.x
Noguchi, Masanori ; Kakuma, Tatsuyuki ; Tomiyasu, Katsuro ; Yamada, Akira ; Itoh, Kyogo ; Konishi, Fumiko ; Kumamoto, Shoichiro ; Shimizu, Kuniyoshi ; Kondo, Ryuichiro ; Matsuoka, Kei. / Randomized clinical trial of an ethanol extract of Ganoderma lucidum in men with lower urinary tract symptoms. In: Asian Journal of Andrology. 2008 ; Vol. 10, No. 5. pp. 777-785.
@article{14b27d63120444faa257588de01e6b42,
title = "Randomized clinical trial of an ethanol extract of Ganoderma lucidum in men with lower urinary tract symptoms",
abstract = "Aim: To evaluate the safety and efficacy of an extract of Ganoderma lucidum that shows the strongest 5α-reductase inhibitory activity among the extracts of 19 edible and medicinal mushrooms by a double-blind, placebo-controlled, randomized and dose-ranging study in men with lower urinary tract symptoms (LUTS). Methods: In this trial, we randomly assigned 88 men over the age of 49 years who had slight-to-moderate LUTS to 12 weeks of treatment with G. lucidum extract (6 mg once a day) or placebo. The primary outcome measures were changes in the International Prostate Symptom Score (IPSS) and variables of uroflowmetry. Secondary outcome measures included changes in prostate size, residual urinary volume after voiding, laboratory values and the reported adverse effects. Results: G. lucidum was effective and significantly superior to placebo for improving total IPSS with 2.1 points decreasing at the end of treatment (mean difference, -1.18 points; 95{\%} confidence interval, -1.74 to -0.62; P < 0.0001). No changes were observed with respect to quality of life scores, peak urinary flow, mean urinary flow, residual urine, prostate volume, serum prostate-specific antigen or testosterone levels. Overall treatment was well tolerated with no severe adverse effects. Conclusion: The extract of G. lucidum was well tolerated and improved IPSS scores. These results encouraged a further, large-scale evaluation of phytotherapy for a long duration using the extract of G. lucidum on men with LUTS.",
author = "Masanori Noguchi and Tatsuyuki Kakuma and Katsuro Tomiyasu and Akira Yamada and Kyogo Itoh and Fumiko Konishi and Shoichiro Kumamoto and Kuniyoshi Shimizu and Ryuichiro Kondo and Kei Matsuoka",
year = "2008",
month = "8",
day = "29",
doi = "10.1111/j.1745-7262.2008.00361.x",
language = "English",
volume = "10",
pages = "777--785",
journal = "Asian Journal of Andrology",
issn = "1008-682X",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Randomized clinical trial of an ethanol extract of Ganoderma lucidum in men with lower urinary tract symptoms

AU - Noguchi, Masanori

AU - Kakuma, Tatsuyuki

AU - Tomiyasu, Katsuro

AU - Yamada, Akira

AU - Itoh, Kyogo

AU - Konishi, Fumiko

AU - Kumamoto, Shoichiro

AU - Shimizu, Kuniyoshi

AU - Kondo, Ryuichiro

AU - Matsuoka, Kei

PY - 2008/8/29

Y1 - 2008/8/29

N2 - Aim: To evaluate the safety and efficacy of an extract of Ganoderma lucidum that shows the strongest 5α-reductase inhibitory activity among the extracts of 19 edible and medicinal mushrooms by a double-blind, placebo-controlled, randomized and dose-ranging study in men with lower urinary tract symptoms (LUTS). Methods: In this trial, we randomly assigned 88 men over the age of 49 years who had slight-to-moderate LUTS to 12 weeks of treatment with G. lucidum extract (6 mg once a day) or placebo. The primary outcome measures were changes in the International Prostate Symptom Score (IPSS) and variables of uroflowmetry. Secondary outcome measures included changes in prostate size, residual urinary volume after voiding, laboratory values and the reported adverse effects. Results: G. lucidum was effective and significantly superior to placebo for improving total IPSS with 2.1 points decreasing at the end of treatment (mean difference, -1.18 points; 95% confidence interval, -1.74 to -0.62; P < 0.0001). No changes were observed with respect to quality of life scores, peak urinary flow, mean urinary flow, residual urine, prostate volume, serum prostate-specific antigen or testosterone levels. Overall treatment was well tolerated with no severe adverse effects. Conclusion: The extract of G. lucidum was well tolerated and improved IPSS scores. These results encouraged a further, large-scale evaluation of phytotherapy for a long duration using the extract of G. lucidum on men with LUTS.

AB - Aim: To evaluate the safety and efficacy of an extract of Ganoderma lucidum that shows the strongest 5α-reductase inhibitory activity among the extracts of 19 edible and medicinal mushrooms by a double-blind, placebo-controlled, randomized and dose-ranging study in men with lower urinary tract symptoms (LUTS). Methods: In this trial, we randomly assigned 88 men over the age of 49 years who had slight-to-moderate LUTS to 12 weeks of treatment with G. lucidum extract (6 mg once a day) or placebo. The primary outcome measures were changes in the International Prostate Symptom Score (IPSS) and variables of uroflowmetry. Secondary outcome measures included changes in prostate size, residual urinary volume after voiding, laboratory values and the reported adverse effects. Results: G. lucidum was effective and significantly superior to placebo for improving total IPSS with 2.1 points decreasing at the end of treatment (mean difference, -1.18 points; 95% confidence interval, -1.74 to -0.62; P < 0.0001). No changes were observed with respect to quality of life scores, peak urinary flow, mean urinary flow, residual urine, prostate volume, serum prostate-specific antigen or testosterone levels. Overall treatment was well tolerated with no severe adverse effects. Conclusion: The extract of G. lucidum was well tolerated and improved IPSS scores. These results encouraged a further, large-scale evaluation of phytotherapy for a long duration using the extract of G. lucidum on men with LUTS.

UR - http://www.scopus.com/inward/record.url?scp=50149114714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50149114714&partnerID=8YFLogxK

U2 - 10.1111/j.1745-7262.2008.00361.x

DO - 10.1111/j.1745-7262.2008.00361.x

M3 - Article

C2 - 18097505

AN - SCOPUS:50149114714

VL - 10

SP - 777

EP - 785

JO - Asian Journal of Andrology

JF - Asian Journal of Andrology

SN - 1008-682X

IS - 5

ER -